The company expects to make the product available in early August 2013.
The new oral contraceptive, norethindrone acetate and ethinyl estradiol chewable tablets and ferrous fumarate tablets, is indicated for use by women of reproductive age to prevent pregnancy.
Warner Chilcott is focused on the women’s healthcare, gastroenterology, urology and dermatology segments of the branded pharmaceuticals market, primarily in North America.